Lung cancers diagnosed at annual CT screening: volume doubling times

PURPOSE

To empirically address the distribution of the volume doubling time (VDT) of lung cancers diagnosed in repeat annual rounds of computed tomographic (CT) screening in the International Early Lung Cancer Action Program (I-ELCAP), first and foremost with respect to rates of tumor growth but also in terms of cell types.

MATERIALS AND METHODS

All CT screenings in I-ELCAP from 1993 to 2009 were performed according to HIPAA-compliant protocols approved by the institutional review boards of the collaborating institutions. All instances of first diagnosis of primary lung cancer after a negative screening result 7-18 months earlier were identified, with symptom-prompted diagnoses included. Lesion diameter was calculated by using the measured length and width of each cancer at the time when the nodule was first identified for further work-up and at the time of the most recent prior screening, 7-18 months earlier. The length and width were measured a second time for each cancer, and the geometric mean of the two calculated diameters was used to calculate the VDT. The χ(2) statistic was used to compare the VDT distributions.

RESULTS

The median VDT for 111 cancers was 98 days (interquartile range, 108). For 56 (50%) cancers it was less than 100 days, and for three (3%) cancers it was more than 400 days. Adenocarcinoma was the most frequent cell type (50%), followed by squamous cell carcinoma (19%), small cell carcinoma (19%), and others (12%). Lung cancers manifesting as subsolid nodules had significantly longer VDTs than those manifesting as solid nodules (P < .0001).

CONCLUSION

Lung cancers diagnosed in annual repeat rounds of CT screening, as manifest by the VDT and cell-type distributions, are similar to those diagnosed in the absence of screening.

Longitudinal predictors of adherence to annual follow-up in a lung cancer screening programme

OBJECTIVE

To examine rates and factors associated with adherence to annual repeat lung cancer screening in two cohorts. Participants and methods The self-pay cohort (n = 2083) was individuals aged 40 years and older with no prior cancer and a smoking history. Participants had to obtain a prescription from their doctor for the low dose, computerized tomography scan (CT), and were responsible for payment of $300 as these CT scans are not typically covered by insurance. The no-pay cohort (n = 1304) was individuals aged 60 and older with a smoking history, and no prior cancer. The initial and one year repeat CT were provided free of charge. Rates of adherence for each cohort were analyzed by demographic variables, smoking history, family history of lung cancer, smoking status (former/current), perceived risk and worry of getting lung cancer and baseline screening CT.

RESULTS

Adherence to annual follow-up was lower for the self-pay than for the no-pay cohort (62% vs. 88%). Both the self-pay and no-pay cohorts had higher adherence rates among Caucasians and those who had a college degree. A greater perceived risk of getting lung cancer increased adherence among the self-pay cohort. Non-calcified nodules found on baseline CT increased the adherence for the self-pay cohort, but decreased the adherence for the no-pay cohort.

CONCLUSIONS

These findings should be used in developing educational materials and targeted retention strategies to increase adherence with repeat lung cancer screening.

Emphysema scores predict death from COPD and lung cancer

OBJECTIVE

Our objective was to assess the usefulness of emphysema scores in predicting death from COPD and lung cancer.

METHODS

Emphysema was assessed with low-dose CT scans performed on 9,047 men and women for whom age and smoking history were documented. Each scan was scored according to the presence of emphysema as follows: none, mild, moderate, or marked. Follow-up time was calculated from time of CT scan to time of death or December 31, 2007, whichever came first. Cox regression analysis was used to calculate the hazard ratio (HR) of emphysema as a predictor of death.

RESULTS

Median age was 65 years, 4,433 (49%) were men, and 4,133 (46%) were currently smoking or had quit within 5 years. Emphysema was identified in 2,637 (29%) and was a significant predictor of death from COPD (HR, 9.3; 95% CI, 4.3-20.2; P < .0001) and from lung cancer (HR, 1.7; 95% CI, 1.1-2.5; P = .013), even when adjusted for age and smoking history.

CONCLUSIONS

Visual assessment of emphysema on CT scan is a significant predictor of death from COPD and lung cancer.

The Lung Image Database Consortium (LIDC) and Image Database Resource Initiative (IDRI): a completed reference database of lung nodules on CT scans

PURPOSE

The development of computer-aided diagnostic (CAD) methods for lung nodule detection, classification, and quantitative assessment can be facilitated through a well-characterized repository of computed tomography (CT) scans. The Lung Image Database Consortium (LIDC) and Image Database Resource Initiative (IDRI) completed such a database, establishing a publicly available reference for the medical imaging research community. Initiated by the National Cancer Institute (NCI), further advanced by the Foundation for the National Institutes of Health (FNIH), and accompanied by the Food and Drug Administration (FDA) through active participation, this public-private partnership demonstrates the success of a consortium founded on a consensus-based process.

METHODS

Seven academic centers and eight medical imaging companies collaborated to identify, address, and resolve challenging organizational, technical, and clinical issues to provide a solid foundation for a robust database. The LIDC/IDRI Database contains 1018 cases, each of which includes images from a clinical thoracic CT scan and an associated XML file that records the results of a two-phase image annotation process performed by four experienced thoracic radiologists. In the initial blinded-read phase, each radiologist independently reviewed each CT scan and marked lesions belonging to one of three categories ("nodule > or =3 mm," "nodule <3 mm," and "non-nodule > or =3 mm"). In the subsequent unblinded-read phase, each radiologist independently reviewed their own marks along with the anonymized marks of the three other radiologists to render a final opinion. The goal of this process was to identify as completely as possible all lung nodules in each CT scan without requiring forced consensus.

RESULTS

The Database contains 7371 lesions marked "nodule" by at least one radiologist. 2669 of these lesions were marked "nodule > or =3 mm" by at least one radiologist, of which 928 (34.7%) received such marks from all four radiologists. These 2669 lesions include nodule outlines and subjective nodule characteristic ratings.

CONCLUSIONS

The LIDC/IDRI Database is expected to provide an essential medical imaging research resource to spur CAD development, validation, and dissemination in clinical practice.

Modeling the mortality reduction due to computed tomography screening for lung cancer

BACKGROUND

The efficacy of computed tomography (CT) screening for lung cancer remains controversial because results from the National Lung Screening Trial are not yet available. In this study, the authors used data from a single-arm CT screening trial to estimate the mortality reduction using a modeling-based approach to construct a control comparison arm.

METHODS

To estimate the potential lung cancer mortality reduction because of CT screening, a previously developed and validated model was applied to the screening trial to predict the number of lung cancer deaths in the absence of screening. By using age, gender, and smoking characteristics matching those of the trial participants, the model was used to simulate 5000 trials in the absence of CT screening to produce the expected number of lung cancer deaths along with 95% confidence intervals (95% CIs), while adjusting for healthy volunteer bias.

RESULTS

There were 64 observed lung cancer deaths in the screening cohort (n = 7995), whereas the model predicted 117.7 deaths (95% CI, 98 deaths-139 deaths), indicating a mortality reduction of 45.6% (P < .001). When a more conservative healthy volunteer adjustment was applied, 111.3 lung cancer deaths were predicted (95% CI, 91 deaths-132 deaths), for a lung cancer-specific mortality reduction of 42.5% (P < .001).

CONCLUSIONS

The results of the current study indicate that CT screening along with early stage treatment can reduce lung cancer-specific mortality. This mortality reduction is greatly influenced by the protocol of nodule follow-up and treatment, and the length of follow-up.

Assessment of lung-cancer mortality reduction from CT Screening

BACKGROUND

CT screening has been shown to increase lung cancer curability and we now assess the corresponding reduction in lung cancer mortality.

METHODS

Lung-cancer mortality in a cohort of 7995 smokers who underwent CT screening for lung cancer in New York State (NYS) was compared with two unscreened cohorts (CPS-II and CARET). The standardized mortality ratio (SMR) of observed to expected lung cancer deaths for NYS was jointly adjusted for age, sex, and smoking history. As more current NYS smokers might have quit as a result of the screening, thus reducing deaths from lung cancer, another analysis was restricted to those participants smoking at entry and still smoking 6 years later.

RESULTS

The SMR was 64/99.8=0.64 (P = 0.84 × 10⁻⁴) and 28/77.6=0.36 (P = 0.83 × 10⁻¹⁰), showing a significant reduction in deaths from lung cancer of 36% and 64% for CPS-II and CARET, respectively. Considering participants who were smoking at entry and still smoking 6 years later, the SMR using CPS-II rates was 29/49.1 = 0.59 (P = 0.001) and using CARET rates it was 21/57.4 = 0.37 (P = 0.31 × 10⁻⁷).

CONCLUSIONS

CT screening significantly reduces lung-cancer mortality.

Ordinal scoring of coronary artery calcifications on low-dose CT scans of the chest is predictive of death from cardiovascular disease

PURPOSE

To assess the usefulness of ordinal scoring of the visual assessment of coronary artery calcification (CAC) on low-dose computed tomographic (CT) scans of the chest in the prediction of cardiovascular death.

MATERIALS AND METHODS

All participants consented to low-dose CT screening according to an institutional review board-approved protocol. The amount of CAC was assessed on ungated low-dose CT scans of the chest obtained between June 2000 and December 2005 in a cohort of 8782 smokers aged 40-85 years. The four main coronary arteries were visually scored, and each participant received a CAC score of 0-12. The date and cause of death was obtained by using the National Death Index. Follow-up time (median, 72.3 months; range, 0.3-91.9 months) was calculated as the time between CT and death, loss to follow-up, or December 31, 2007, whichever came first. Logistic regression analysis was used to determine the risk of mortality according to CAC category adjusted for age, pack-years of cigarette smoking, and sex. The same analysis to determine the hazard ratio for survival from cardiac death was performed by using Cox regression analysis.

RESULTS

The rate of cardiovascular deaths increased with an increasing CAC score and was 1.2% (43 of 3573 subjects) for a score of 0, 1.8% (66 of 3569 subjects) for a score of 1-3, 5.0% (51 of 1015 subjects) for a score of 4-6, and 5.3% (33 of 625 subjects) for a score of 7-12. With use of subjects with a CAC score of 0 as the reference group, a CAC score of at least 4 was a significant predictor of cardiovascular death (odds ratio [OR], 4.7; 95% confidence interval: 3.3, 6.8; P < .0001); when adjusted for sex, age, and pack-years of smoking, the CAC score remained significant (OR, 2.1; 95% confidence interval: 1.4, 3.1; P = .0002).

CONCLUSION

Visual assessment of CAC on low-dose CT scans provides clinically relevant quantitative information as to cardiovascular death.

Post-CABG coronary CT angiography: radiation dose and graft image quality in retrospective versus prospective ECG gating

RATIONALE AND OBJECTIVES

The aim of this study was to compare effective radiation doses between prospective and retrospective electrocardiographic gating during coronary computed tomographic angiography for coronary artery bypass grafting evaluation.

MATERIALS AND METHODS

Fifty consecutive coronary computed tomographic angiographic exams for coronary artery bypass grafting evaluation, 25 prospectively gated and 25 retrospectively gated, were reviewed from January 8, 2008, to June 16, 2009. Body mass index and image quality were also compared between the two groups. To minimize the potential bias introduced by differences in torso length, the effective radiation dose from each exam was measured and normalized to a 24-cm z-axis scan length for all patients. Pooled t tests were used to compare the prospectively and retrospectively gated groups.

RESULTS

The average effective doses delivered in the retrospective and prospective groups were 40.8 mSv (standard error [SE], 1.8 mSv) and 8.6 mSv (SE, 0.7 mSv), respectively. When normalized to the average z-axis scan length of 24 cm, the effective dose in the retrospective group, 38.4 mSv (SE, 1.3 mSv), was still >4 times greater than that in the prospective group, 9.1 mSv (SE, 0.7 mSv) (P < .0001). There was no significant difference in body mass index or image quality between the groups.

CONCLUSIONS

Effective radiation dose in coronary computed tomographic angiography for coronary artery bypass grafting evaluation is very high because of long scan lengths. Prospective electrocardiographic gating significantly reduces effective radiation dose by an average of 76% compared to retrospectively gated scans (9.1 vs 38.4 mSv). In the coronary artery bypass grafting population, prospective electrocardiographic gating should be used whenever ventricular functional assessment is not required.

Zone of transition: a potential source of error in tumor volume estimation

PURPOSE

To measure the width of the zone of transition (ZOT) between nonaerated solid tumor and surrounding nonneoplastic lung parenchyma and determine the extent to which ZOT influences computer-derived estimates of tumor volume based on computed tomographic (CT) images.

MATERIALS AND METHODS

This HIPAA-compliant study was approved by the institutional research board. The histologic slide containing the maximum tumor area was digitized for 20 consecutive patients with solid adenocarcinoma. The outer border of the tumor (A2) was marked; it included all lung parenchyma having any tumor cells. The inner border of the tumor (A1) was marked; it included only solid tumor where lung parenchyma was no longer preserved. Assuming two circles with areas of A2 and A1, the corresponding two radii, R2 and R1, were calculated. The average width of the ZOT was defined as R2 minus R1. The relationship between ZOT and tumor diameter on the CT images prior to surgery was assessed by using regression analysis. The relationship between ZOT and tumor volume was assessed by using a theoretical model of idealized spheres with varying diameters.

RESULTS

The mean width of the ZOT was 0.78 mm (median, 0.48 mm). The proportional effect of ZOT on tumor volume estimates decreased with increasing tumor diameter and increased with increasing width of ZOT. Correlation between ZOT and tumor diameter was not significant (P = .87).

CONCLUSION

The average width of ZOT is about a single pixel width on a full field of view CT scan; thus, the ZOT can have a large effect on volume estimates, particularly for small tumors.

Automated nodule location and size estimation using a multi-scale Laplacian of Gaussian filtering approach

Estimation of nodule location and size is an important pre-processing step in some nodule segmentation algorithms to determine the size and location of the region of interest. Ideally, such estimation methods will consistently find the same nodule location regardless of where the the seed point (provided either manually or by a nodule detection algorithm) is placed relative to the "true" center of the nodule, and the size should be a reasonable estimate of the true nodule size. We developed a method that estimates nodule location and size using multi-scale Laplacian of Gaussian (LoG) filtering. Nodule candidates near a given seed point are found by searching for blob-like regions with high filter response. The candidates are then pruned according to filter response and location, and the remaining candidates are sorted by size and the largest candidate selected. This method was compared to a previously published template-based method. The methods were evaluated on the basis of stability of the estimated nodule location to changes in the initial seed point and how well the size estimates agreed with volumes determined by a semi-automated nodule segmentation method. The LoG method exhibited better stability to changes in the seed point, with 93% of nodules having the same estimated location even when the seed point was altered, compared to only 52% of nodules for the template-based method. Both methods also showed good agreement with sizes determined by a nodule segmentation method, with an average relative size difference of 5% and -5% for the LoG and template-based methods respectively.

Estimation of anatomical locations using standard frame of reference in chest CT scans

We propose a method to establish the standard chest frame of reference (CFOR) using the rib cage in a lung CT scan. Such a reference frame is essential for referring to a certain location within a chest region and may facilitate the registration across multiple scans of a given subject as well as the comparative studies within a cohort of subjects. The robustness of the established CFOR was evaluated by estimating the anatomical locations within chest in the follow-up scan given the location in the first scan. Specifically, tracheal bifurcation point of airway tree and the center of pulmonary nodule were used as the anatomical points of interest. The CFOR was also used for exploring the spatial distribution of the anatomical location for a large number of individuals. The results show that on average the point of interest can be estimated accurately within 10.3 mm for the bifurcation point and within 12.5 mm for the pulmonary nodule's center point. Further analyzing the spatial distribution of the CFOR coordinates across 86 subjects shows that we can localize the bifurcation point to the small subregion within the CFOR.

Pulmonary lymphoma identified as a result of low-dose CT screening for lung cancer

PURPOSE

To describe the frequency and findings of pulmonary lymphoma in asymptomatic people undergoing computed tomographic (CT) screening for lung cancer.

METHODS

All lymphoma diagnoses resulting from CT screening of 31 567 at-risk subjects (median age, 61 years) were identified, and the CT images were reviewed to document the lesions as to number, location, density, shape, and margin. The presence of lymphadenopathy and pleural effusion was also documented.

RESULTS

Five patients with pulmonary lymphoma were identified. The lymphoma was a B-cell lymphoma in three, Hodgkin's lymphoma in one, and malignant lymphoma in one; it was primary in four and secondary in one. One patient had two lesions; the other four patients each had one lesion. Four of the six lesions were a mass, and two were a nodule. Four of the lesions had irregular margins. Air bronchograms were seen in three. Growth assessment was useful in leading to decisions for biopsy.

CONCLUSION

In a context of CT screening to detect lung cancer in asymptomatic volunteers, the diagnosis of pulmonary lymphoma was rare but, nevertheless, occurred in five (.016%) of 31 567 volunteers.

Left ventricular papillary muscles and trabeculae are significant determinants of cardiac MRI volumetric measurements: Effects on clinical standards in patients with advanced systolic dysfunction

BACKGROUND

Left ventricular (LV) mass and ejection fraction are of diagnostic and therapeutic importance in patients with systolic dysfunction. Cardiac MRI (CMR) has been proposed as a standard for these indices. Prior studies have variably included papillary muscles and trabeculae in either intracavitary or myocardial volumes. Quantitative effects and clinical implications of this methodological difference in patients with systolic dysfunction are unknown.

METHODS

Fifty consecutive patients with known systolic dysfunction (EF<40%) underwent CMR. LV volumes were determined using previously established methods: Method 1 included papillary muscles and trabeculae in cavity volume, method 2 included these in myocardial volume. Both methods were used for each patient with tracings superimposed to isolate papillary/trabecular volume and insure consistency of other endocardial contours. Readers applied methods in random order blinded to clinical findings and results of the other method.

RESULTS

LV mass differed substantially by method (p<0.001) with absolute difference of 16.6%. Ejection fraction differed by 3 points (p<0.001) with absolute differences of > or =5 points in 16% of patients. Mean differences in LV mass and ejection fraction were produced by consistent methodological differences on a per-patient basis. Methodology used produced differences in patients meeting established criteria for LV hypertrophy (28% vs. 60%, p<0.001) and ICD implantation (64% vs. 48%, p<0.01).

CONCLUSIONS

LV mass and ejection fraction differ significantly between commonly employed CMR methods. Alternative inclusion of papillary muscles and trabeculae in either cavity or myocardial volumes produces significant differences in clinical and therapeutic indices that can affect management of patients with advanced systolic dysfunction.

CT screening for lung cancer: update 2007

Screening is the pursuit of the early diagnosis of cancer before symptoms occur. The purpose of early diagnosis is to provide early treatment, which potentially prevents death from the cancer. The usefulness of screening depends on how early the cancer can be diagnosed and how many deaths can be prevented by early treatment as compared with later symptom-prompted diagnosis and treatment. The goal of the Early Lung Cancer Action Project investigators was to develop an efficient methodology that would provide an ever-accumulating, continually updated body of evidence for evaluation of emerging new technologies for screening for cancer. This methodology recognizes that screening is a sequential process that starts with the pursuit of the early diagnosis of cancer followed by early treatment. It also recognizes that diagnostic research is fundamentally different from treatment research. To fully understand the current discussions on the evidence for lung cancer screening, key definitions are provided, including the differentiation between the first, baseline round of screening and all subsequent rounds of repeat screening and baseline and repeat cancers and their distribution by cell type. These definitions are critical in analyzing the results of various screening reports as they are not used by all. To provide optimal screening, a regimen for the diagnostic workup must be specified starting with the definition of the initial test, its positive result, and the workup for a positive result leading to a diagnosis of cancer. Assessment of diagnostic performance does not require a control group, but does require confirmation of the diagnosis. For assessment of the effectiveness of early treatment, a comparison group is needed. The comparison group may be formed by randomly assigning people with screen-diagnosed lung cancer to immediate or delayed treatment, as has been done for prostate cancer. This provides a direct assessment of any potential overdiagnosis of the cancer resulting from screening. Alternatively, a quasiexperimental control group can be used consisting of participants diagnosed with the cancer who have refused or delayed their treatment even though they are candidates for it.

Molecular characterization of small peripheral lung tumors based on the analysis of fine needle aspirates

The computed tomography (CT)-based early lung cancer diagnostic technologies allow the detection of very small stage I lung tumors. As part of these screening protocols any suspicious nodule has to be diagnosed morphologically, which requires CT-guided Fine Needle Aspiration, open biopsy or surgery. Fine Needle Aspiration (FNA) cytology is a well-recognised method for a rapid and accurate diagnosis of small lung tumors. Molecular analysis of the FNA specimens could complement cytology diagnosis by the characterization of the biological traits at the preoperative stage. In this study, we aimed to characterize the biological profile of 33 paraffin-embedded transthoracic FNA samples obtained from three groups of lung cancer patients: two groups of small early-detected lung adenocarcinomas (radiologically subsolid and solid nodules) and a third group of small metastatic adenocarcinomas. Genetic analysis was performed by fluorescence in situ hybridization using the four-color LAVysion probe. p53 and Ki-67 protein expression was also evaluated by immunocytochemistry. The samples showed gains for all targets analyzed; two cases had EGFR gene amplification and two cases had MYC amplification. There were no significant differences in the percentage of genetically malignant cells and the expression of Ki-67 among the three groups. However, p53 accumulation was significantly higher in the metastatic group compared to the subsolid early-detected group (P = 0.001). In conclusion, molecular analysis of FNA specimens may provide useful information at preoperative stages. In our series, a good prognostic profile in subsolid early detected adenocarcinomas is suggested.

The Lung Image Database Consortium (LIDC): an evaluation of radiologist variability in the identification of lung nodules on CT scans

RATIONALE AND OBJECTIVES

The purpose of this study was to analyze the variability of experienced thoracic radiologists in the identification of lung nodules on computed tomography (CT) scans and thereby to investigate variability in the establishment of the "truth" against which nodule-based studies are measured.

MATERIALS AND METHODS

Thirty CT scans were reviewed twice by four thoracic radiologists through a two-phase image annotation process. During the initial "blinded read" phase, radiologists independently marked lesions they identified as "nodule >or=3 mm (diameter)," "nodule <3 mm," or "non-nodule >or=3 mm." During the subsequent "unblinded read" phase, the blinded read results of all four radiologists were revealed to each radiologist, who then independently reviewed their marks along with the anonymous marks of their colleagues; a radiologist's own marks then could be deleted, added, or left unchanged. This approach was developed to identify, as completely as possible, all nodules in a scan without requiring forced consensus.

RESULTS

After the initial blinded read phase, 71 lesions received "nodule >or=3 mm" marks from at least one radiologist; however, all four radiologists assigned such marks to only 24 (33.8%) of these lesions. After the unblinded reads, a total of 59 lesions were marked as "nodule >or=3 mm" by at least one radiologist. Twenty-seven (45.8%) of these lesions received such marks from all four radiologists, three (5.1%) were identified as such by three radiologists, 12 (20.3%) were identified by two radiologists, and 17 (28.8%) were identified by only a single radiologist.

CONCLUSION

The two-phase image annotation process yields improved agreement among radiologists in the interpretation of nodules >or=3 mm. Nevertheless, substantial variability remains across radiologists in the task of lung nodule identification.